TY - JOUR
T1 - EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors
T2 - A single institution experience
AU - Jabbour, Elias
AU - Cortes, Jorge
AU - Nazha, Aziz
AU - O'Brien, Susan
AU - Quintas-Cardama, Alfonso
AU - Pierce, Sherry
AU - Garcia-Manero, Guillermo
AU - Kantarjian, Hagop
PY - 2012/5/10
Y1 - 2012/5/10
N2 - To validate the recently reported European Treatment and Outcomes Study (EUTOS) score, we applied it to 465 patients with early chronic phase chronic myeloid leukemia treated with standard-dose imatinib (n ∇ 71), high-dose imatinib (n ∇ 208), or second-generation tyrosine kinase inhibitors (n ∇ 186), and assessed its ability to predict event-free survival (EFS), transformation-free survival (TFS), and overall survival (OS). The median follow-up was 69 months. The overall complete cytogenetic response and major molecular response rates were 92% and 85%, respectively. The 3-year EFS, TFS, and OS rates were 86%, 95%, and 97%, respectively. Of the 465 patients, 427 (92%) were in low EUTOS score category. There was no difference in the major molecular response, TFS, EFS, and OS rates between patients with low and high EUTOS score, overall and within specific therapies. In conclusion, 8% of patients with chronic phase chronic myeloid leukemia treated at our institution are in the high EUTOS score; in this population, the EUTOS score was not predictive for outcome.
AB - To validate the recently reported European Treatment and Outcomes Study (EUTOS) score, we applied it to 465 patients with early chronic phase chronic myeloid leukemia treated with standard-dose imatinib (n ∇ 71), high-dose imatinib (n ∇ 208), or second-generation tyrosine kinase inhibitors (n ∇ 186), and assessed its ability to predict event-free survival (EFS), transformation-free survival (TFS), and overall survival (OS). The median follow-up was 69 months. The overall complete cytogenetic response and major molecular response rates were 92% and 85%, respectively. The 3-year EFS, TFS, and OS rates were 86%, 95%, and 97%, respectively. Of the 465 patients, 427 (92%) were in low EUTOS score category. There was no difference in the major molecular response, TFS, EFS, and OS rates between patients with low and high EUTOS score, overall and within specific therapies. In conclusion, 8% of patients with chronic phase chronic myeloid leukemia treated at our institution are in the high EUTOS score; in this population, the EUTOS score was not predictive for outcome.
UR - http://www.scopus.com/inward/record.url?scp=84860910581&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84860910581&partnerID=8YFLogxK
U2 - 10.1182/blood-2011-10-388967
DO - 10.1182/blood-2011-10-388967
M3 - Article
C2 - 22431574
AN - SCOPUS:84860910581
SN - 0006-4971
VL - 119
SP - 4524
EP - 4526
JO - Blood
JF - Blood
IS - 19
ER -